[{"id":"3aa72670-9b0b-4205-9807-1cc48204caf9","acronym":"","url":"https://clinicaltrials.gov/study/NCT05335941","created_at":"2022-04-20T16:53:38.622Z","updated_at":"2025-02-25T15:35:35.713Z","phase":"Phase 2","brief_title":"A Phase 2 Study to Evaluate the Triplet Combination of Pemetrexed Plus AB928 (Etrumadenant) + AB122 (Zimberelimab) in Patients With Previously Treated Advanced or Metastatic MTAP Deficient Urothelial Carcinoma","source_id_and_acronym":"NCT05335941","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" MTAP • IL17A","pipe":"","alterations":" ","tags":["MTAP • IL17A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e pemetrexed • Yutuo (zimberelimab) • etrumadenant (AB928)"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 06/13/2023","start_date":" 06/13/2023","primary_txt":" Primary completion: 09/30/2025","primary_completion_date":" 09/30/2025","study_txt":" Completion: 09/30/2025","study_completion_date":" 09/30/2025","last_update_posted":"2025-02-10"},{"id":"24c0fcb4-b357-4530-a6a0-668b57518e71","acronym":"ARC-27","url":"https://clinicaltrials.gov/study/NCT06120075","created_at":"2023-11-07T16:14:23.781Z","updated_at":"2025-02-25T17:32:32.864Z","phase":"Phase 1","brief_title":"A Study of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies","source_id_and_acronym":"NCT06120075 - ARC-27","lead_sponsor":"Arcus Biosciences, Inc.","biomarkers":" EGFR • PD-L1 • ALK • MET • RET • ROS1 • STK11 • NTRK","pipe":" | ","alterations":" EGFR mutation • STK11 mutation • ALK mutation","tags":["EGFR • PD-L1 • ALK • MET • RET • ROS1 • STK11 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • STK11 mutation • ALK mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • Yutuo (zimberelimab)"],"overall_status":"Recruiting","enrollment":" Enrollment 91","initiation":"Initiation: 01/19/2024","start_date":" 01/19/2024","primary_txt":" Primary completion: 11/01/2026","primary_completion_date":" 11/01/2026","study_txt":" Completion: 11/01/2026","study_completion_date":" 11/01/2026","last_update_posted":"2025-01-30"},{"id":"4f7b2be7-d23d-40b8-a5c9-76b1850fdede","acronym":"","url":"https://clinicaltrials.gov/study/NCT04736173","created_at":"2021-02-03T16:02:06.319Z","updated_at":"2024-07-02T16:34:37.611Z","phase":"Phase 3","brief_title":"Study Comparing the Combination Domvanalimab and Zimberelimab With Pembrolizumab in Untreated Locally Advanced or Metastatic PD-L1-High Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT04736173","lead_sponsor":"Arcus Biosciences, Inc.","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression • PD-L1 overexpression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • PD-L1 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • carboplatin • paclitaxel • pemetrexed • Yutuo (zimberelimab) • domvanalimab (AB154) • mitazalimab (ADC-1013)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 169","initiation":"Initiation: 02/08/2021","start_date":" 02/08/2021","primary_txt":" Primary completion: 08/31/2024","primary_completion_date":" 08/31/2024","study_txt":" Completion: 07/01/2027","study_completion_date":" 07/01/2027","last_update_posted":"2024-06-06"},{"id":"6bb1edff-f3e6-46a7-a9e0-e5a2bfe3f8ab","acronym":"EDGE-Gastric","url":"https://clinicaltrials.gov/study/NCT05329766","created_at":"2023-01-23T16:59:58.940Z","updated_at":"2024-07-02T16:34:38.031Z","phase":"Phase 2","brief_title":"A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies","source_id_and_acronym":"NCT05329766 - EDGE-Gastric","lead_sponsor":"Arcus Biosciences, Inc.","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • oxaliplatin • Yutuo (zimberelimab) • leucovorin calcium • domvanalimab (AB154) • quemliclustat (AB680)"],"overall_status":"Recruiting","enrollment":" Enrollment 360","initiation":"Initiation: 06/10/2022","start_date":" 06/10/2022","primary_txt":" Primary completion: 09/01/2026","primary_completion_date":" 09/01/2026","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2024-06-05"},{"id":"607d2950-c677-467b-8196-ea2b0e2b9d8e","acronym":"VELOCITY-Lung","url":"https://clinicaltrials.gov/study/NCT05633667","created_at":"2022-12-01T15:57:15.119Z","updated_at":"2024-07-02T16:34:58.933Z","phase":"Phase 2","brief_title":"Study of Novel Treatment Combinations in Patients With Lung Cancer","source_id_and_acronym":"NCT05633667 - VELOCITY-Lung","lead_sponsor":"Gilead Sciences","biomarkers":" EGFR • PD-L1 • ALK","pipe":"","alterations":" ","tags":["EGFR • PD-L1 • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • cisplatin • carboplatin • docetaxel • albumin-bound paclitaxel • pemetrexed • Yutuo (zimberelimab) • Trodelvy (sacituzumab govitecan-hziy) • domvanalimab (AB154) • etrumadenant (AB928)"],"overall_status":"Recruiting","enrollment":" Enrollment 397","initiation":"Initiation: 03/16/2023","start_date":" 03/16/2023","primary_txt":" Primary completion: 01/01/2027","primary_completion_date":" 01/01/2027","study_txt":" Completion: 01/01/2027","study_completion_date":" 01/01/2027","last_update_posted":"2024-06-04"},{"id":"15f2feeb-91bd-4d1e-8210-eb0dea4872da","acronym":"ARC-7","url":"https://clinicaltrials.gov/study/NCT04262856","created_at":"2021-01-18T20:42:57.527Z","updated_at":"2024-07-02T16:35:00.997Z","phase":"Phase 2","brief_title":"Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer","source_id_and_acronym":"NCT04262856 - ARC-7","lead_sponsor":"Arcus Biosciences, Inc.","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression • PD-L1 overexpression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • PD-L1 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Yutuo (zimberelimab) • domvanalimab (AB154) • etrumadenant (AB928) • mitazalimab (ADC-1013)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 151","initiation":"Initiation: 05/28/2020","start_date":" 05/28/2020","primary_txt":" Primary completion: 02/01/2025","primary_completion_date":" 02/01/2025","study_txt":" Completion: 02/01/2025","study_completion_date":" 02/01/2025","last_update_posted":"2024-05-24"},{"id":"409dc71f-d788-44b0-9225-6f9acd37a635","acronym":"ARC-4","url":"https://clinicaltrials.gov/study/NCT03846310","created_at":"2021-01-18T18:59:18.192Z","updated_at":"2024-07-02T16:35:01.028Z","phase":"Phase 1","brief_title":"A Study to Evaluate Immunotherapy Combinations in Participants With Lung Cancer","source_id_and_acronym":"NCT03846310 - ARC-4","lead_sponsor":"Arcus Biosciences, Inc.","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • carboplatin • pemetrexed • Yutuo (zimberelimab) • etrumadenant (AB928)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 77","initiation":"Initiation: 04/01/2019","start_date":" 04/01/2019","primary_txt":" Primary completion: 08/01/2024","primary_completion_date":" 08/01/2024","study_txt":" Completion: 08/01/2024","study_completion_date":" 08/01/2024","last_update_posted":"2024-05-24"},{"id":"7fc0fb06-d255-4be4-aba4-ae25c5e3da72","acronym":"","url":"https://clinicaltrials.gov/study/NCT04087018","created_at":"2021-02-09T08:59:18.309Z","updated_at":"2024-07-02T16:35:00.967Z","phase":"Phase 1","brief_title":"Study to Evaluate Safety and Clinical Activity of AB122 in Biomarker Selected Participants With Advanced Solid Tumors","source_id_and_acronym":"NCT04087018","lead_sponsor":"Arcus Biosciences, Inc.","biomarkers":" TMB","pipe":" | ","alterations":" TMB-H","tags":["TMB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TMB-H"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Yutuo (zimberelimab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 09/24/2019","start_date":" 09/24/2019","primary_txt":" Primary completion: 09/01/2024","primary_completion_date":" 09/01/2024","study_txt":" Completion: 09/01/2024","study_completion_date":" 09/01/2024","last_update_posted":"2024-05-24"},{"id":"f40873ca-e3ed-4dcf-90c0-5527c131aaed","acronym":"","url":"https://clinicaltrials.gov/study/NCT05891171","created_at":"2023-06-06T14:07:07.271Z","updated_at":"2024-07-02T16:35:01.204Z","phase":"Phase 1","brief_title":"Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers","source_id_and_acronym":"NCT05891171","lead_sponsor":"Arcus Biosciences, Inc.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • 5-fluorouracil • pemetrexed • oxaliplatin • Yutuo (zimberelimab) • leucovorin calcium • AB598"],"overall_status":"Recruiting","enrollment":" Enrollment 81","initiation":"Initiation: 10/13/2023","start_date":" 10/13/2023","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 08/01/2025","study_completion_date":" 08/01/2025","last_update_posted":"2024-05-24"},{"id":"1a85dab3-0f07-4f86-8f14-7eca6a3d7503","acronym":"ELEVATE HNSCC","url":"https://clinicaltrials.gov/study/NCT04854499","created_at":"2021-04-22T20:53:31.234Z","updated_at":"2024-07-02T16:35:02.553Z","phase":"Phase 2","brief_title":"Study of Magrolimab Combination Therapy in Patients With Head and Neck Squamous Cell Carcinoma","source_id_and_acronym":"NCT04854499 - ELEVATE HNSCC","lead_sponsor":"Gilead Sciences","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • carboplatin • docetaxel • 5-fluorouracil • Yutuo (zimberelimab) • magrolimab (ONO-7913)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 230","initiation":"Initiation: 09/07/2021","start_date":" 09/07/2021","primary_txt":" Primary completion: 07/01/2025","primary_completion_date":" 07/01/2025","study_txt":" Completion: 07/01/2025","study_completion_date":" 07/01/2025","last_update_posted":"2024-05-20"},{"id":"0a6115e7-c012-4d05-b47c-86e7c080cae9","acronym":"","url":"https://clinicaltrials.gov/study/NCT05130177","created_at":"2021-11-23T14:53:41.387Z","updated_at":"2024-07-02T16:35:05.811Z","phase":"Phase 2","brief_title":"Zimberelimab (AB122) With TIGIT Inhibitor Domvanalimab (AB154) in PD-1 Relapsed/Refractory Melanoma","source_id_and_acronym":"NCT05130177","lead_sponsor":"Diwakar Davar","biomarkers":" BRAF • CTLA4","pipe":" | ","alterations":" BRAF mutation","tags":["BRAF • CTLA4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Yutuo (zimberelimab) • domvanalimab (AB154)"],"overall_status":"Recruiting","enrollment":" Enrollment 26","initiation":"Initiation: 03/16/2022","start_date":" 03/16/2022","primary_txt":" Primary completion: 01/01/2027","primary_completion_date":" 01/01/2027","study_txt":" Completion: 01/01/2030","study_completion_date":" 01/01/2030","last_update_posted":"2024-05-06"},{"id":"1cb5fcda-fc0d-47da-bc21-1ef95536ae56","acronym":"STAR-121","url":"https://clinicaltrials.gov/study/NCT05502237","created_at":"2022-08-16T11:56:10.218Z","updated_at":"2024-07-02T16:35:06.556Z","phase":"Phase 3","brief_title":"Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT05502237 - STAR-121","lead_sponsor":"Gilead Sciences","biomarkers":" EGFR • BRAF • ALK • RET • NTRK","pipe":" | ","alterations":" BRAF mutation • ALK mutation • RET mutation","tags":["EGFR • BRAF • ALK • RET • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • ALK mutation • RET mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • carboplatin • albumin-bound paclitaxel • pemetrexed • Yutuo (zimberelimab) • domvanalimab (AB154)"],"overall_status":"Recruiting","enrollment":" Enrollment 720","initiation":"Initiation: 10/12/2022","start_date":" 10/12/2022","primary_txt":" Primary completion: 09/01/2027","primary_completion_date":" 09/01/2027","study_txt":" Completion: 09/01/2027","study_completion_date":" 09/01/2027","last_update_posted":"2024-05-01"},{"id":"f5b1a6c8-e4d4-430b-b708-74c9cb48dc4a","acronym":"","url":"https://clinicaltrials.gov/study/NCT04791839","created_at":"2021-03-10T12:55:03.832Z","updated_at":"2024-07-02T16:35:10.680Z","phase":"Phase 2","brief_title":"Safety and Efficacy of Zimberelimab (AB122) in Combination With Domvanalimab (AB154) and Etrumadenant (AB928) in Patients With Previously Treated Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT04791839","lead_sponsor":"Washington University School of Medicine","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Yutuo (zimberelimab) • domvanalimab (AB154) • etrumadenant (AB928)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 08/04/2021","start_date":" 08/04/2021","primary_txt":" Primary completion: 01/31/2025","primary_completion_date":" 01/31/2025","study_txt":" Completion: 04/30/2029","study_completion_date":" 04/30/2029","last_update_posted":"2024-04-09"},{"id":"cee8aba7-65f5-4dfb-8178-d79ff5369a64","acronym":"","url":"https://clinicaltrials.gov/study/NCT04999761","created_at":"2021-08-11T15:53:36.773Z","updated_at":"2024-07-02T16:35:19.007Z","phase":"Phase 1","brief_title":"AB122 Platform Study","source_id_and_acronym":"NCT04999761","lead_sponsor":"Taiho Pharmaceutical Co., Ltd.","biomarkers":" KRAS • NRAS","pipe":" | ","alterations":" KRAS mutation • NRAS mutation • KRAS wild-type • RAS wild-type • NRAS wild-type • KRAS exon 2 mutation","tags":["KRAS • NRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • NRAS mutation • KRAS wild-type • RAS wild-type • NRAS wild-type • KRAS exon 2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Cyramza (ramucirumab) • Lytgobi (futibatinib) • Yutuo (zimberelimab) • Lonsurf (trifluridine/tipiracil) • Jeselhy (pimitespib) • pamufetinib (TAS-115)"],"overall_status":"Recruiting","enrollment":" Enrollment 715","initiation":"Initiation: 06/01/2021","start_date":" 06/01/2021","primary_txt":" Primary completion: 05/01/2026","primary_completion_date":" 05/01/2026","study_txt":" Completion: 05/01/2026","study_completion_date":" 05/01/2026","last_update_posted":"2024-02-16"},{"id":"491d898f-8337-422d-865b-11073ce2b8d3","acronym":"ZODIAC","url":"https://clinicaltrials.gov/study/NCT06250036","created_at":"2024-02-08T19:21:26.261Z","updated_at":"2024-07-02T16:35:20.138Z","phase":"Phase 2","brief_title":"Peri-operative Zimberelimab (Anti-PD-1) vs Zimberelimab in Combination With Domvanalimab (Anti-TIGIT) in Resectable Mismatch Repair Deficient/Micro-satellite Unstable Gastric and Gastro-oesophageal Junctional Adenocarcinoma (ZODIAC)","source_id_and_acronym":"NCT06250036 - ZODIAC","lead_sponsor":"Royal Marsden NHS Foundation Trust","biomarkers":" MSI","pipe":" | ","alterations":" MSI-H/dMMR","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Yutuo (zimberelimab) • domvanalimab (AB154)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 04/01/2024","start_date":" 04/01/2024","primary_txt":" Primary completion: 09/01/2026","primary_completion_date":" 09/01/2026","study_txt":" Completion: 09/01/2031","study_completion_date":" 09/01/2031","last_update_posted":"2024-02-08"},{"id":"5f4970ad-dbcd-4dde-a9ae-985f376b7430","acronym":"","url":"https://clinicaltrials.gov/study/NCT06055738","created_at":"2023-09-28T16:11:03.369Z","updated_at":"2024-07-02T16:35:35.635Z","phase":"Phase 2","brief_title":"Zimberelimab Combined With Albumin-bound Paclitaxel and Cisplatin in Neoadjuvant Treatment of LACC","source_id_and_acronym":"NCT06055738","lead_sponsor":"Tang-Du Hospital","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • albumin-bound paclitaxel • Yutuo (zimberelimab)"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 10/09/2023","start_date":" 10/09/2023","primary_txt":" Primary completion: 12/30/2026","primary_completion_date":" 12/30/2026","study_txt":" Completion: 12/30/2027","study_completion_date":" 12/30/2027","last_update_posted":"2023-09-27"},{"id":"f7965fe6-2b5d-45ba-a8fe-8f1d78d763eb","acronym":"","url":"https://clinicaltrials.gov/study/NCT05798819","created_at":"2023-04-05T14:03:19.649Z","updated_at":"2025-03-03T12:18:58.519Z","phase":"Phase 3","brief_title":"A Study of GLS-010 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer","source_id_and_acronym":"NCT05798819","lead_sponsor":"Guangzhou Gloria Biosciences Co., Ltd.","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • cisplatin • carboplatin • paclitaxel • Yutuo (zimberelimab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 424","initiation":"Initiation: 05/01/2023","start_date":" 05/01/2023","primary_txt":" Primary completion: 05/01/2025","primary_completion_date":" 05/01/2025","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2023-04-05"},{"id":"2ffd0727-21d5-4ad0-b0f4-c41acaec7074","acronym":"","url":"https://clinicaltrials.gov/study/NCT05759312","created_at":"2023-03-08T17:01:34.794Z","updated_at":"2024-07-02T16:35:53.762Z","phase":"Phase 1/2","brief_title":"Zimberelimab Plus Metformin for Recurrent Ovarian Clear Cell Carcinoma","source_id_and_acronym":"NCT05759312","lead_sponsor":"Fudan University","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Yutuo (zimberelimab) • metformin"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 03/01/2023","start_date":" 03/01/2023","primary_txt":" Primary completion: 02/01/2025","primary_completion_date":" 02/01/2025","study_txt":" Completion: 02/01/2025","study_completion_date":" 02/01/2025","last_update_posted":"2023-03-08"},{"id":"3603d9cb-e037-4690-8fd9-ed03f30069ff","acronym":"","url":"https://clinicaltrials.gov/study/NCT05437692","created_at":"2022-06-29T14:59:21.733Z","updated_at":"2024-07-02T16:36:02.577Z","phase":"Phase 2","brief_title":"Zimberelimab Combined With Concurrent Radiotherapy and Chemotherapy for Locally Advanced Cervical Cancer","source_id_and_acronym":"NCT05437692","lead_sponsor":"Shanghai Zhongshan Hospital","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • paclitaxel • Yutuo (zimberelimab)"],"overall_status":"Recruiting","enrollment":" Enrollment 19","initiation":"Initiation: 07/15/2022","start_date":" 07/15/2022","primary_txt":" Primary completion: 07/01/2024","primary_completion_date":" 07/01/2024","study_txt":" Completion: 07/01/2025","study_completion_date":" 07/01/2025","last_update_posted":"2022-10-12"},{"id":"9814b72e-e5b0-47e3-8862-2044e2a0eab8","acronym":"RIGHT","url":"https://clinicaltrials.gov/study/NCT05540483","created_at":"2022-09-14T17:55:36.567Z","updated_at":"2024-07-02T16:36:03.806Z","phase":"Phase 2","brief_title":"RC-48 Combined With GLS-010 in HER2-overexpressed Patients With Previously Treated Unresectable Biliary Tract Cancer","source_id_and_acronym":"NCT05540483 - RIGHT","lead_sponsor":"The First Affiliated Hospital with Nanjing Medical University","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 overexpression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Aidixi (disitamab vedotin) • Yutuo (zimberelimab)"],"overall_status":"Recruiting","enrollment":" Enrollment 31","initiation":"Initiation: 08/01/2022","start_date":" 08/01/2022","primary_txt":" Primary completion: 08/01/2024","primary_completion_date":" 08/01/2024","study_txt":" Completion: 08/01/2025","study_completion_date":" 08/01/2025","last_update_posted":"2022-09-16"},{"id":"1a3278af-54da-45bb-8ebe-dbf62f81687f","acronym":"","url":"https://clinicaltrials.gov/study/NCT05221775","created_at":"2022-02-05T18:29:08.590Z","updated_at":"2024-07-02T16:36:17.644Z","phase":"Phase 1","brief_title":"Safety of XELOX Combined With GLS-010 and Lenvatinib in Advanced AFP-positive Gastric Cancer Patients","source_id_and_acronym":"NCT05221775","lead_sponsor":"Tianjin Medical University Cancer Institute and Hospital","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lenvima (lenvatinib) • capecitabine • oxaliplatin • Yutuo (zimberelimab)"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 11/01/2021","start_date":" 11/01/2021","primary_txt":" Primary completion: 03/01/2023","primary_completion_date":" 03/01/2023","study_txt":" Completion: 10/01/2023","study_completion_date":" 10/01/2023","last_update_posted":"2022-02-03"},{"id":"87dfc3a6-4586-48b9-9349-f22cbe094a43","acronym":"","url":"https://clinicaltrials.gov/study/NCT03972722","created_at":"2021-01-17T18:05:00.860Z","updated_at":"2024-07-02T16:36:59.060Z","phase":"Phase 2","brief_title":"Study of GLS-010 Injection in Patients With Recurrent or Metastatic Cervical Cancer","source_id_and_acronym":"NCT03972722","lead_sponsor":"Guangzhou Gloria Biosciences Co., Ltd.","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Yutuo (zimberelimab)"],"overall_status":"Recruiting","enrollment":" Enrollment 89","initiation":"Initiation: 05/15/2019","start_date":" 05/15/2019","primary_txt":" Primary completion: 05/15/2022","primary_completion_date":" 05/15/2022","study_txt":" Completion: 05/15/2023","study_completion_date":" 05/15/2023","last_update_posted":"2019-06-05"}]